Literature DB >> 3120474

Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations.

G J Kontoghiorghes1.   

Abstract

Increased 59Fe excretion was observed following the intragastric and intraperitoneal administration of 1-ethyl- and 1-methyl-2-methyl-3-hydroxypyrid-4-ones in normal and iron-loaded, 59Fe-labelled mice, respectively. Administration of these chelators and desferrioxamine parenterally or intragastrically to an iron-loaded rabbit caused no increase in Cu, Zn, Ca or Mg urinary excretion. Iron mobilisation was also observed following the incubation of the chelators with ferritin and haemosiderin but not with haemoglobin. Desferrioxamine under the same conditions caused methaemoglobin formation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120474     DOI: 10.1159/000205877

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  9 in total

1.  Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells.

Authors:  G J Kontoghiorghes; A May
Journal:  Biol Met       Date:  1990

2.  [Effect of Maillard products and lysinoalanine on the bioavailability of iron, copper and zinc].

Authors:  G Rehner; T Walter
Journal:  Z Ernahrungswiss       Date:  1991-02

3.  Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP,L1).

Authors:  R Lange; W Lameijer; C Slijkhuis; D de Kaste
Journal:  Pharm World Sci       Date:  1996-08

4.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

5.  The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.

Authors:  J Y Jeremy; G J Kontoghiorghes; A V Hoffbrand; P Dandona
Journal:  Biochem J       Date:  1988-08-15       Impact factor: 3.857

Review 6.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 7.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 8.  Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine.

Authors:  Viktor A Timoshnikov; Olga Yu Selyutina; Nikolay E Polyakov; Victoria Didichenko; George J Kontoghiorghes
Journal:  Int J Mol Sci       Date:  2022-01-23       Impact factor: 5.923

Review 9.  Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.

Authors:  George J Kontoghiorghes; Christina N Kontoghiorghe
Journal:  Cells       Date:  2020-06-12       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.